Adenosine receptors in cerebral ischemia

International Review of Neurobiology

Volumn 119, Issue , 2014, Pages 309-348

  Melani, Alessia ^a   Pugliese, Anna Maria ^a   Pedata, Felicita ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adenosine; Adenosine receptor; Brain; Cerebral ischemia; Excitotoxicity; Neuroinflammation

Indexed keywords

2 CHLOROADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 AMINO 8 CHLORO 1 PHENYL 1,2,4 TRIAZOLO[4,3 A]QUINOXALINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 ETHYL 2 PHENYL 4 PROPYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; FRACTALKINE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MRS 1706; N (4 ACETYLPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)HENOXY]ACETAMIDE; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; UNCLASSIFIED DRUG; PURINERGIC RECEPTOR AFFECTING AGENT;

ARTICLE; BRAIN ISCHEMIA; DISEASE MODEL; DRUG MECHANISM; ENZYME ACTIVATION; EXCITOTOXICITY; HIPPOCAMPAL CA1 REGION; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM;

ANIMALS; BRAIN ISCHEMIA; HUMANS; PURINERGIC AGENTS; RECEPTORS, PURINERGIC P1;

EID: 84906725168     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801022-8.00013-1     Document Type: Chapter

References (275)

1. Abbracchio M.P., Cattabeni F. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Annals of the New York Academy of Sciences 1999, 890:79-92.
2. Adair T.H. Growth regulation of the vascular system: An emerging role for adenosine. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2005, 289:R283-R296.
3. 2A knockout mice. Stroke 2003, 34:739-744.
4. Amisten S., Braun O.O., Bengtsson A., Erlinge D. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thrombosis Research 2008, 122:47-57.
5. Andiné P. Involvement of adenosine in ischemic and postischemic calcium regulation. Molecular and Chemistry Neuropathology 1993, 18:35-49.
6. 1 receptors impairs the recovery of synaptic transmission after hypoxia. Neuroscience 2005, 132:575-580.
7. Attali B., Wang N., Kolot A., Sobko A., Cherepanov V., Soliven B. Characterization of delayed rectifier Kv channels in oligodendrocytes and progenitor cells. Journal of Neuroscience 1997, 17:8234-8245.
8. Baines A.E., Corrêa S.A., Irving A.J., Frenguelli B.G. Differential trafficking of adenosine receptors in hippocampal neurons monitored using GFP- and super-ecliptic pHluorin-tagged receptors. Neuropharmacology 2011, 61:1-11.
9. Baraldi P.G., Cacciari B., Romagnoli R., Merighi S., Varani K., Borea P.A., et al. A(3) adenosine receptor ligands: History and perspectives. Medicinal Research Reviews 2000, 20:103-128.
10. Barone F.C., Feuerstein G.Z. Inflammatory mediators and stroke: New opportunities for novel therapeutics. Journal of Cerebral Blood Flow and Metabolism 1999, 19:819-834.
11. Barone F.C., Irving E.A., Ray A.M., Lee J.C., Kassis S., Kumar S., et al. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Medicinal Research Reviews 2001, 21:129-145.
12. 3 receptors protect astrocytes from hypoxic damage. European Journal of Pharmacology 2008, 596:6-13.
13. Boissard C.G., Lindner M.D., Gribkoff V.K. Hypoxia produces cell death in the rat hippocampus in the presence of an A1 adenosine receptor antagonist: An anatomical and behavioral study. Neuroscience 1992, 48:807-812.
14. Bona E., Aden U., Gilland E., Fredholm B.B., Hagberg H. Neonatal cerebral hypoxia-ischemia: The effect of adenosine receptor antagonists. Neuropharmacology 1997, 36:1327-1338.
15. Bonetti B., Stegagno C., Cannella B., Rizzato N., Moretto G., Raine C.S. Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. American Journal of Pathology 1999, 155:1433-1438.
16. Borea P.A., Gessi S., Bar-Yehuda S., Fishman P. A3 adenosine receptor: Pharmacology and role in disease. Handbook of Experimental Pharmacology 2009, 193:297-327.
17. Borsello T., Clarke P.G., Hirt L., Vercelli A., Repici M., Schorderet D.F., et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nature Medicine 2003, 9:1180-1186.
18. 2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Letters 1998, 429:139-142.
19. Bruce-Keller A.J. Microglial-neuronal interactions in synaptic damage and recovery. Journal of Neuroscience Research 1999, 58:191-201.
20. 3 receptor activity disrupts neutrophil migratory capacity and impacts innate immune function in vivo. European Journal of Immunology 2012, 42:3358-3368.
21. 2A analogue improves neurologic outcome after spinal cord trauma in the rabbit. Journal of Trauma 2002, 53:225-229.
22. Castillo A., Tolón M.R., Fernández-Ruiz J., Romero J., Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiology of Disease 2010, 37:434-440.
23. Chauhan N.K., Young A.M., Gibson C.L., Davidson C. Inhibition of pre-ischeamic conditioning in the mouse caudate brain slice by NMDA- or adenosine A1 receptor antagonists. European Journal of Pharmacology 2013, 698:322-329.
24. Chen G.J., Harvey B.K., Shen H., Chou J., Victor A., Wang Y. Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. Journal of Neuroscience Research 2006, 84:1848-1855.
25. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. Journal of Neuroscience 1999, 19:9192-9200.
26. Chen F., Qi Z., Luo Y., Hinchliffe T., Ding G., Xia Y., et al. Non-pharmaceutical therapies for stroke: Mechanisms and clinical implications. Progress in Neurobiology 2014, 115C:246-269.
27. Choi D.W. Possible mechanisms limiting N-methyl-D-aspartate receptor overactivation and the therapeutic efficacy of N-methyl-D-aspartate antagonists. Stroke 1990, 21:III20-III22.
28. 3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats. American Journal of Pathology 2011, 179:2042-2052.
29. 2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Molecular Medicine 2008, 14:116-123.
30. Cipriani R., Villa P., Chece G., Lauro C., Paladini A., Micotti E., et al. CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. Journal of Neuroscience 2011, 31:16327-16335.
31. 2A receptor heteromers. Journal of Neuroscience 2006, 26:2080-2087.
32. 1 receptors in the rat hippocampus. Neuroscience 2006, 138:1195-1203.
33. Colotta V., Catarzi D., Varano F., Capelli F., Lenzi O., Filacchioni G., et al. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. Journal of Medicinal Chemistry 2007, 50:4061-4074.
34. Colotta V., Catarzi D., Varano F., Lenzi O., Filacchioni G., Martini C., et al. Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists. Bioorganic & Medicinal Chemistry 2008, 16:6086-6102.
35. Colotta V., Lenzi O., Catarzi D., Varano F., Filacchioni G., Martini C., et al. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. Journal of Medicinal Chemistry 2009, 52:2407-2419.
36. 2A receptors inhibit delayed rectifier potassium currents and cell differentiation in primary purified oligodendrocyte cultures. Neuropharmacology 2013, 73:301-310.
37. Corradetti R., Lo Conte G., Moroni F., Passani M.B., Pepeu G. Adenosine decreases aspartate and glutamate release from rat hippocampal slices. European Journal of Pharmacology 1984, 104:19-26.
38. 2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport 2000, 11:2591-2595.
39. +-evoked glutamate release in vivo in young and aged rats. Neuroreport 1999, 10:687-691.
40. 2A receptor ligands. Handbook of Experimental Pharmacology 2009, 193:59-98.
41. 2A receptors enhance GABA transport into nerve terminals by restraining PKC inhibition of GAT-1. Journal of Neurochemistry 2009, 109:336-347.
42. Cui M., Bai X., Li T., Chen F., Dong Q., Zhao Y., et al. Decreased extracellular adenosine levels lead to loss of hypoxia-induced neuroprotection after repeated episodes of exposure to hypoxia. PLoS One 2013, 8:e57065.
43. Cunha R.A. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: Different roles, different sources and different receptors. Neurochemistry International 2001, 38:107-125.
44. 2A receptors in the rat hippocampus. Brain Research 1994, 649:208-216.
45. 2A receptor regulation of neuroinflammation and traumatic brain injury. Journal of Neuroscience 2010, 30:5802-5810.
46. Dale N., Pearson T., Fringuelli B.G. Direct measurement of adenosine release during hypoxia in the CA1 region of the rat hippocampal slice. Journal of Physiology 2000, 526(Pt1):143-155.
47. Daval J.L., Nicolas F. Opposite effects of cyclohexyladenosine and theophylline on hypoxic damage in cultured neurons. Neuroscience Letters 1994, 175:114-116.
48. 1-receptors, guanine nucleotide and forskolin binding sites following transient brain ischemia: A quantitative autoradiographic study. Brain Research 1989, 491:212-226.
49. De Keyser J., Sulter G., Luiten P.G. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing?. Trends in Neuroscience 1999, 22:535-540.
50. 3 receptors. The Journal of Neuroscience 2011, 31:11941-11952.
51. 2A receptors. Hippocampus 2007, 17:577-585.
52. 2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. Journal of Neuroscience 2004, 24:2905-2913.
53. Dirnagl U. Pathobiology of injury after stroke: The neurovascular unit and beyond. Annals of the New York Academy of Sciences 2012, 1268:21-25.
54. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischaemic stroke: An integrated view. Trends in Neuroscience 1999, 22:391-397.
55. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. British Journal of Pharmacology 1996, 118:1461-1468.
56. Domenici M.R., de Carolis A.S., Sagratella S. Block by N6-L-phenylisopropyl-adenosine of the electrophysiological and morphological correlates of hippocampal ischaemic injury in the gerbil. British Journal of Pharmacology 1996, 118:1551-1557.
57. Dunwiddie T.V. Interactions between the effects of adenosine and calcium on synaptic responses in rat hippocampus in vitro. Journal of Physiology 1984, 350:545-559.
58. 2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 2008, 111:2024-2035.
59. 2B adenosine receptors. Circulation 2007, 115:1581-1590.
60. Ekdahl C.T., Claasen J.H., Bonde S., Kokaia Z., Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:13632-13637.
61. Ekdahl C.T., Kokaia Z., Lindvall O. Brain inflammation and adult neurogenesis: The dual role of microglia. Neuroscience 2009, 158:1021-1029.
62. 2B receptors. Journal of Experimental Medicine 2003, 198:783-796.
63. Eltzschig H.K., Thompson L.F., Karhausen J., Cotta R.J., Ibla J.C., Robson S.C., et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: Coordination by extracellular nucleotide metabolism. Blood 2004, 104:3986-3992.
64. Evans M.C., Swan J.H., Meldrum B.S. An adenosine analogue, 2-chloroadenosine, protects against long term development of ischaemic cell loss in the rat hippocampus. Neuroscience Letters 1987, 83:287-292.
65. Fedorova I.M., Jacobson M.A., Basile A., Jacobson K.A. Behavioral characterization of mice lacking the A3 adenosine receptor: Sensitivity to hypoxic neurodegeneration. Cellular and Molecular Neurobiology 2003, 23:431-447.
66. 2B receptors in inflammation. Advances in Pharmacology 2011, 61:115-144.
67. 2B receptors in angiogenic factor regulation. Circulation Research 2002, 90:531-538.
68. 2B angiogenic phenotype. Hypertension 2004, 44:649-654.
69. 2A-receptors. Glia 1996, 18:152-160.
70. 2 dopamine receptors in rat striatum. Brain Research. Molecular Brain Research 1992, 14:186-195.
71. 3 receptor subtype. Current Topics in Medicinal Chemistry 2003, 3:463-469.
72. 3 adenosine receptor agonists. Drug Discovery Today 2012, 17:359-366.
73. Fowler J.C. Adenosine antagonists delay hypoxia-induced depression of neuronal activity in hippocampal brain slice. Brain Research 1989, 490:378-384.
74. Fowler J.C. Adenosine antagonists alter the synaptic response to in vitro ischemia in the rat hippocampus. Brain Research 1990, 509:331-334.
75. Fowler J.C., Gervitz L.M., Hamilton M.E., Walker J.A. Systemic hypoxia and the depression of synaptic transmission in rat hippocampus after carotid artery occlusion. Journal of Physiology 2003, 550:961-972.
76. Fredholm B.B., Arslan G., Halldner L., Kull B., Schulte G., Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's Archives of Pharmacology 2000, 362:364-374.
77. Fredholm B.B., Chen J.F., Masino S.A., Vaugeois J.M. Actions of adenosine at its receptors in the CNS: Insights from knockouts and drugs. Annual Review of Pharmacology and Toxicology 2005, 45:385-412.
78. 2A receptors and therapeutic applications. Current Topics in Medicinal Chemistry 2003, 3:413-426.
79. Fredholm B.B., IJzerman A.P., Jacobson K.A., Linden J., Müller C.E. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacological Review 2011, 63:1-34.
80. 2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leucocytes. Naunyn-Schmiedeberg's Archives of Pharmacology 1996, 354:262-267.
81. Frenguelli B.G., Wigmore G., Llaudet E., Dale N. Temporal and mechanistic dissociation of ATP and adenosine release during ischaemia in the mammalian hippocampus. Journal of Neurochemistry 2007, 101:1400-1413.
82. 2A receptor antagonism after focal cerebral ischemia in spontaneously hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology 2014, 387:165-173.
83. 2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sciences 1994, 55:L61-L65.
84. Gelderblom M., Eminel S., Herdegen T., Waetzig V. c-Jun N-terminal kinases (JNKs) and the cytoskeleton-functions beyond neurodegeneration. International Journal of Developmental Neuroscience 2004, 22:559-564.
85. Gelderblom M., Leypoldt F., Steinbach K., Behrens D., Choe C.U., Siler D.A., et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009, 40:1849-1857.
86. 2A receptor agonist CGS21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord. Shock 2009, 32:578-585.
87. 2A receptor agonists reduce the apoptosis in an experimental model of spinal cord trauma. Journal of Biological Regulators & Homeostatic Agents 2010, 24:73-86.
88. Gervitz L.M., Davies D.G., Omidvar K., Fowler J.C. The effect of acute hypoxemia and hypotension on adenosine-mediated depression of evoked hippocampal synaptic transmission. Experimental Neurology 2003, 182:507-517.
89. Gervitz L.M., Lutherer L.O., Davies D.G., Pirch J.H., Fowler J.C. Adenosine induces initial hypoxic-ischemic depression of synaptic transmission in the rat hippocampus in vivo. American Journal of Physiology, Regulative Integrative and Comparative Physiology 2001, 280:R639-R645.
90. 3 adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes. Pharmacological Research 2013, 76:157-170.
91. 3 adenosine receptor: An enigmatic player in cell biology. Pharmacology & Therapeutics 2008, 117:123-140.
92. 3 adenosine receptors in human lymphocytes: Up-regulation in T cell activation. Molecular Pharmacology 2004, 65:711-719.
93. 2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20. Molecular Pharmacology 2005, 67:2137-2147.
94. Gibson C.L. Cerebral ischemic stroke: Is gender important?. Journal of Cerebral Blood Flow & Metabolism 2013, 33:1355-1361.
95. Goldberg M.P., Monyer H., Weiss J.H., Choi D.W. Adenosine reduces cortical neuronal injury induced by oxygen or glucose deprivation in vitro. Neuroscience Letters 1988, 89:323-327.
96. Gomes C.V., Kaster M.P., Tomé A.R., Agostinho P.M., Cunha R.A. Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration. Biochimica et Biophysica Acta 2011, 1808:1380-1399.
97. González-Fernández E., Sánchez-Gómez M.V., Pérez-Samartín A., Arellano R.O., Matute C. A3 adenosine receptors mediate oligodendrocyte death and ischemic damage to optic nerve. Glia 2014, 62:199-216.
98. Gourine A.V., Dale N., Gourine V.N., Spyer K.M. Fever in systemic inflammation: Roles of purines. Frontiers in Bioscience 2004, 9:1011-1022.
99. 2B adenosine receptor stimulation. Investigative Ophthalmology & Visual Science 2001, 42:2068-2073.
100. Greene R.W., Haas H.L. The electrophysiology of adenosine in the mammalian central nervous system. Progress in Neurobiology 1991, 36:329-341.
101. Gribkoff V.K., Bauman L.A., VanderMaelen C.P. The adenosine antagonist 8-cyclopentyltheophylline reduces the depression of hippocampal neuronal responses during hypoxia. Brain Research 1990, 512:353-357.
102. Gu L., Huang B., Shen W., Gao L., Ding Z., Wu H., et al. Early activation of nSMase2/ceramide pathway in astrocytes is involved in ischemia-associated neuronal damage via inflammation in rat hippocampi. Journal of Neuroinflammation 2013, 10:109-124.
103. 2A receptor deficiency reduces striatal glutamate outflow and attenuates brain injury induced by transient focal cerebral ischemia in mice. Brain Research 2009, 1297:185-193.
104. 2A receptor-dependent and independent mechanisms. FASEB Journal 2000, 14:2065-2074.
105. Haskó G., Linden J., Cronstein B., Pacher P. Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nature Reviews Drug Discovery 2008, 7:759-770.
106. 2A-receptors. Neuroscience Letters 1997, 231:83-86.
107. 3 receptors by endogenous adenosine inhibits synaptic transmission during hypoxia in rat cortical neurons. Restorative Neurology and Neuroscience 2003, 21:55-63.
108. 1 adenosine receptor agonist on the neurochemical, behavioral and histological consequences of ischemia. Brain Research 1994, 641:217-224.
109. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. Journal of Comparative Neurology 2001, 431:331-346.
110. + channels in cerebral ischemic preconditioning. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:4666-4670.
111. Higashi H., Meno J.R., Marwaha A.S., Winn H.R. Hippocampal injury and neurobehavioral deficits following hyperglycemic cerebral ischemia: Effect of theophylline and ZM241385. Journal of Neurosurgery 2002, 96:117-126.
112. Hirt L., Badaut J., Thevenet J., Granziera C., Regli L., Maurer F., et al. D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 2004, 35:1738-1743.
113. Howe C.L., Bieber A.J., Warrington A.E., Pease L.R., Rodriguez M. Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiology of Disease 2004, 15:120-131.
114. 1 receptor and redox status after transient focal cerebral ischemia in rats. Brain Research 2012, 1459:81-90.
115. Iadecola C., Anrather J. Stroke research at a crossroad: Asking the brain for directions. Nature Neuroscience 2011, 14:1363-1368.
116. 1 receptors promotes post-ischemic electrocortical burst suppression. Neuroscience 2009, 159:1070-1078.
117. Irving E.A., Barone F.C., Reith A.D., Hadingham S.J., Parsons A.A. Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat. Brain Research. Molecular Brain Research 2000, 77:65-75.
118. Jacobson K.A. Adenosine A3 receptors: Novel ligands and paradoxical effect. Trends in Pharmacological Sciences 1998, 19(5):184-191.
119. Jacobson K.A. Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates. Journal of Medicinal Chemistry 2013, 56:3749-3767.
120. Jacobson K.A., Hoffmann C., Cattabeni F., Abbracchio M.P. Adenosine-induced cell death: Evidence for receptor-mediated signalling. Apoptosis 1999, 4:197-211.
121. Jacobson K.A., Von Lubitz D.K., Daly J.W., Fredholm B.B. Adenosine receptor ligands: Differences with acute versus chronic treatment. Trends in Pharmacological Sciences 1996, 17:108-113.
122. Jarrott D.M., Domer F.R. A gerbil model of cerebral ischemia suitable for drug evaluation. Stroke 1980, 11:203-209.
123. 2A receptor up-regulates BDNF expression in rat primary cortical neurons. Neurochemical Research 2011, 36:2259-2269.
124. 1 receptor. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:9407-9412.
125. Johnston A., Gudjonsson J.E., Sigmundsdottir H., Ludviksson B.R., Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clinical Immunology 2005, 114:154-163.
126. 2A receptor agonists and antagonists. Neuroscience 1998, 85:229-237.
127. 2A receptor antagonist. Brain Research 1998, 800:328-335.
128. Jurewicz A., Matysiak M., Andrzejak S., Selmaj K. TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway. Glia 2006, 53:158-166.
129. 2A receptor induces GDNF expression by the Stat3 signal in vitro. Neuroreport 2012, 23:958-962.
130. Kitada M., Rowitch D.H. Transcription factor co-expression patterns indicate heterogeneity of oligodendroglial subpopulations in adult spinal cord. Glia 2006, 54:35-46.
131. Kitagawa H., Mori A., Shimada J., Mitsumoto Y., Kikuchi T. Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats. Neurological Research 2002, 24:317-323.
132. 2B adenosine receptors in tissue protection. Advances in Pharmacology 2011, 61:145-186.
133. 2B adenosine receptor-mediated process. Journal of Immunology 2012, 188:445-453.
134. Kuan C.Y., Whitmarsh A.J., Yang D.D., Liao G., Schloemer A.J., Dong C., et al. A critical role of neural-specific JNK3 for ischemic apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:15184-15189.
135. 1 receptor gene expression in cerebral ischemia of Wistar rats. Neuroscience Letters 2005, 387:59-61.
136. Lange-Asschenfeldt C., Raval A.P., Dave K.R., Mochly-Rosen D., Sick T.J., Perez-Pinzon M.A. Epsilon protein kinase C mediated ischemic tolerance requires activation of the extracellular regulated kinase pathway in the organotypic hippocampal slice. Journal of Cerebral Blood Flow and Metabolism 2004, 24:636-645.
137. 2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. Journal of Experimental Medicine 2006, 203:2639-2648.
138. 2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices. British Journal of Pharmacology 1999, 128:1035-1044.
139. Latini S., Bordoni F., Pedata F., Corradetti R. Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. British Journal of Pharmacology 1999, 127:729-739.
140. Latini S., Pedata F. Adenosine in the central nervous system: Release mechanisms and extracellular concentrations. Journal of Neurochemistry 2001, 79:463-484.
141. 1 receptors. Brain Research 1993, 609:313-315.
142. Lewis A.J., Manning A.M. New targets for anti-inflammatory drugs. Current Opinion in Chemical Biology 1999, 3:489-494.
143. 2A receptor on non-bone marrow-derived cells. Neuroscience 2006, 141:2029-2039.
144. Liang R., Pang Z.P., Deng P., Xu Z.C. Transient enhancement of inhibitory synaptic transmission in hippocampal CA1 pyramidal neurons after cerebral ischemia. Neuroscience 2009, 160:412-418.
145. 1 receptor activation preferentially protects cultured cerebellar neurons versus astrocytes against hypoxia-induced death. Molecular and Chemical Neuropathology 1997, 31:119-133.
146. 1 receptor responses. European Journal of Pharmacology 1999, 383:395-398.
147. Lopes L.V., Sebastião A.M., Ribeiro J.A. Adenosine and related drugs in brain diseases: Present and future in clinical trials. Current Topics in Medicinal Chemistry 2011, 11:1087-1101.
148. Lu A., Tang Y., Ran R., Clark J.F., Aronow B.J., Sharp F.R. Genomics of the periinfarction cortex after focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism 2003, 23:786-810.
149. Lu X.C., Williams A.J., Yao C., Berti R., Hartings J.A., Whipple R., et al. Microarray analysis of acute and delayed gene expression profile in rats after focal ischemic brain injury and reperfusion. Journal of Neuroscience Research 2004, 77:843-857.
150. 3 receptor agonist reduces early brain injury in subarachnoid haemorrhage. Neuroreport 2010, 21:892-896.
151. 2A adenosine receptors. Neuropharmacology 2013, 67:511-520.
152. 2A adenosine receptor blockade. Neuropharmacology 2004, 47:884-891.
153. 2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology 2003, 45:201-210.
154. Marks L., Carswell H.V., Peters E.E., Graham D.I., Patterson J., Dominiczak A.F., et al. Characterization of the microglial response to cerebral ischemia in the stroke-prone spontaneously hypertensive rat. Hypertension 2001, 38:116-122.
155. +-ATPase-α2 controlling glutamate uptake in astrocytes. Journal of Neuroscience 2013, 33:18492-18502.
156. 2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia 2012, 60:702-716.
157. Matsumoto K., Graf R., Rosner G., Shimada N., Heiss W.D. Flow thresholds for extracellular purine catabolite elevation in cat focal ischemia. Brain Research 1992, 579:309-314.
158. Matute C., Alberdi E., Ibarretxe G., Sanchez-Gomez M.V. Excitotoxicity in glial cells. European Journal of Pharmacology 2002, 447:239-246.
159. Matute C., Sanchez-Gomez M.V., Martinez-Millan L., Miledi R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:8830-8835.
160. McDonald J.W., Althomsons S.P., Hyrc K.L., Choi D.W., Goldberg M.P. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nature Medicine 1998, 4:291-297.
161. Medina-Pulido L., Molina-Arcas M., Justicia C., Soriano E., Burgaya F., Planas A.M., et al. Hypoxia and P1 receptor activation regulate the high-affinity concentrative adenosine transporter CNT2 in differentiated neuronal PC12 cells. Biochemical Journal 2013, 454:437-445.
162. 2A receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain 2009, 132:1480-1495.
163. Melani A., Corti F., Cellai L., Vannucchi M.G., Pedata F. Time-related protection of adenosine A2A antagonists and agonists after focal cerebral ischemia 2012.
164. 2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia. Brain Research 2014, 1551:59-72.
165. Melani A., Corti F., Stephan H., Müller C.E., Donati C., Bruni P., et al. Ecto-ATPase inhibition: ATP and adenosine release under physiological and ischemic in vivo conditions in the rat striatum. Experimental Neurology 2012, 233:193-204.
166. 2A receptors on modulation of oligodendroglia in cerebral ischemia. Shock 2011, 36(Suppl. 1):24.
167. 2A receptor antagonist SCH58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Research 2006, 1073-1074:470-480.
168. 2A receptor antagonist SCH58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Research 2003, 959:243-250.
169. Melani A., Pantoni L., Corsi C., Bianchi L., Monopoli A., Bertorelli R., et al. Striatal outflow of adenosine, excitatory amino acids, γ-aminobutyric acid, and taurine in awake freely moving rats after middle cerebral artery occlusion. Correlations with neurological deficit and histopatological damage. Stroke 1999, 30:2448-2455.
170. 2A adenosine receptors by SCH58261 results in neuroprotective effects in cerebral ischaemia in rats. NeuroReport 1998, 9:3955-3959.
171. Mori M., Nishizaki T., Okada Y. Protective effect of adenosine on the anoxic damage of hippocampal slice. Neuroscience 1992, 46:301-307.
172. 1 receptor binding in the post-ischaemic rat brain. Neuroreport 1994, 5:1453-1456.
173. 1 receptor antagonist. Journal of Cerebral Blood Flow and Metabolism 2002, 22:161-170.
174. 1 receptors with (11)C-MPDX as an indicator of severe cerebral ischemic insult. Journal of Nuclear Medicine 2003, 44:1839-1844.
175. Newman G.C., Hospod F.E., Trowbridge S.D., Motwani S., Liu Y. Restoring adenine nucleotides in a brain slice model of cerebral reperfusion. Journal of Cerebral Blood Flow and Metabolism 1998, 18:675-685.
176. 2A adenosine receptors. Glia 2002, 39:133-147.
177. O'Bryant Z., Vann K.T., Xiong Z.G. Translational strategies for neuroprotection in ischemic stroke-focusing on Acid-sensing ion channel 1a. Translational Stroke Research 2014, 5:59-68.
178. 2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005, 129:26-33.
179. 2 receptor-mediated responses in the rat hippocampus in vitro. European Journal of Pharmacology 1998, 362:17-25.
180. 1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro. European Journal of Neuroscience 2004, 20:1197-1204.
181. 2A receptors and neuroprotection. Annals of the New York Academy of Sciences 1997, 825:30-48.
182. 1 binding sites after transient forebrain ischemia in the gerbil. Brain Research 1987, 415:309-322.
183. 2 adenosine receptor agonist CGS21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neuroscience Letters 1992, 138:169-172.
184. 3 adenosine receptor. Evidence for a G-protein-coupled receptor kinase-mediated mechanism. The Journal of Biological Chemistry 1995, 270:29607-29613.
185. 2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects. Journal of Neuroinflammation 2011, 8:31-44.
186. 2A receptor antagonism in cerebral ischemia. Neurological Research 2005, 27:169-174.
187. Pedata F., Latini S., Pugliese A.M., Pepeu G. Investigations into the adenosine outflow from hippocampal slices evoked by ischemia-like conditions. Journal of Neurochemistry 1993, 61:284-289.
188. Pedata F., Pugliese A.M., Coppi E., Popoli P., Morelli M., Schwarzschild M.A., et al. Adenosine in the central nervous system: Effects on neurotransmission and neuroprotection. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 2007, 4:304-321.
189. 3 adenosine receptors from cell biology to pharmacology and therapeutics 2010, 165-188. Springer, Netherlands. P.A. Borea (Ed.).
190. Perez-Pinzon M.A., Mumford P.L., Rosenthal M., Sick T.J. Anoxic preconditioning in hippocampal slices: Role of adenosine. Neuroscience 1996, 75:687-694.
191. 2A adenosine receptor gene. Journal of Neurochemistry 1996, 66:362-368.
192. 2A adenosine receptors leads to c-fos inhibition in a rat model of brain ischemia. Pharmacological Research 2002, 45:125-128.
193. 2A adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Research 1995, 705:79-84.
194. Phillis J.W. Adenosine and adenine nucleotides as regulators of cerebral blood flow: Roles of acidosis, cell swelling, and K ATP channels. Critical Reviews in Neurobiology 2004, 16:237-270.
195. Phillis J.W., Goshgarian H.G. Adenosine and neurotrauma: Therapeutic perspectives. Neurological Research 2001, 23:183-189.
196. Phillis J.W., Smith-Barbour M., O'Regan M.H. Changes in extracellular amino acid neurotransmitters and purines during and following ischemias of different durations in the rat cerebral cortex. Neurochemistry International 1996, 29:115-120.
197. Piao C.S., Kim J.B., Han P.L., Lee J.K. Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. Journal of Neuroscience Research 2003, 73:537-544.
198. 2A receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus. Journal of Neurochemistry 2005, 93:595-604.
199. 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. Journal of Neurochemistry 2004, 89:152-156.
200. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. European Journal of Pharmacology 1995, 287:215-217.
201. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. The Journal of Neuroscience 2002, 22:1967-1975.
202. 2B receptor. Molecular Pharmacology 1995, 47:1126-1132.
203. Pugliese A.M., Coppi E., Spalluto G., Corradetti R., Pedata F. A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro. British Journal of Pharmacology 2006, 147:524-532.
204. Pugliese A.M., Coppi E., Volpini R., Cristalli G., Corradetti R., Jeong L.S., et al. Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. Biochemical Pharmacology 2007, 74:768-779.
205. Pugliese A.M., Latini S., Corradetti R., Pedata F. Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: Role of adenosine receptors. British Journal of Pharmacology 2003, 140:305-314.
206. 2A receptor antagonist ZM241385 enhances neuronal survival after oxygen-glucose deprivation in rat CA1 hippocampal slices. British Journal of Pharmacology 2009, 157:818-830.
207. Ribeiro J.A., Sebastiao A.M., de Mendonca A. Adenosine receptors in the nervous system: Pathophysiological implications. Progress in Neurobiology 2002, 68:377-392.
208. Rivkees S.A., Zhao Z., Porter G., Turner C. Influences of adenosine on the fetus and newborn. Molecular Genetics and Metabolism 2001, 74:160-171.
209. 2A receptors in brain: Morphological substrates for integration of striatal function. Neurology 2003, 61:S10-S11.
210. 1 receptors by caffeine treatment. Neuroscience Letters 1989, 103:275-280.
211. Rudolphi K.A., Keil M., Hinze H.J. Effect of theophylline on ischemically induced hippocampal damage in Mongolian gerbils: A behavioral and histopathological study. Journal of Cerebral Blood Flow and Metabolism 1987, 7:74-81.
212. Saransaari P., Oja S.S. GABA release modified by adenosine receptors in mouse hippocampal slices under normal and ischemic conditions. Neurochemical Research 2005, 30:467-473.
213. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study. Journal of Neurochemistry 1991, 57:1062-1067.
214. 2A subtype receptor agonists. British Journal of Pharmacology 2005, 144:642-650.
215. 2A receptor agonist CGS21680. European Journal of Pharmacology 2004, 484:269-275.
216. Schwartz-Bloom R.D., Sah R. Gamma-aminobutyric acid(A) neurotransmission and cerebral ischemia. Journal of Neurochemistry 2001, 77:353-371.
217. 2A antagonists in PD. Neurology 2002, 58:1154-1160.
218. Sebastião A.M., Cunha R.A., de Mendonca A., Ribeiro J.A. Modification of adenosine modulation of synaptic transmission in the hippocampus of aged rats. British Journal of Pharmacology 2000, 131:1629-1634.
219. Sebastião A.M., de Mendonca A., Moreira T., Ribeiro J.A. Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. The Journal of Neuroscience 2001, 21:8564-8571.
220. 2 receptor-mediated excitatory actions on the nervous system. Progress in Neurobiology 1996, 48:167-189.
221. 2A receptor activation: Implications for neuroprotection. British Journal of Pharmacology 2009, 158:15-22.
222. 2A receptor agonist CGS21680. Drug Development Research 1996, 39:108-114.
223. Shrager P., Novakovic S.D. Control of myelination, axonal growth, and synapse formation in spinal cord explants by ion channels and electrical activity. Brain Research. Developmental Brain Research 1995, 88:68-78.
224. Simpson R.E., O'Regan M.H., Perkins L.M., Phillis J.W. Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: Effects of adenosine receptor agonists and antagonists. Journal of Neurochemistry 1992, 58:1683-1690.
225. 2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochemical Pharmacology 2003, 65:493-501.
226. 2A receptors. Annual Review of Immunology 2004, 22:657-682.
227. Soler E.P., Ruiz V.C. Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: Similarities and differences. Current Cardiology Reviews 2010, 6:138-149.
228. Somjen G.G. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiological Reviews 2001, 81:1065-1096.
229. Stoll G., Jander S., Schroeter M. Inflammation and glial responses in ischemic brain lesions. Progress in Neurobiology 1998, 56:149-171.
230. 2A receptor antagonist. Journal of Neuroscience Research 2007, 85:1077-1085.
231. Sutherland G.R., Peeling J., Lesiuk H.J., Brownstone R.M., Rydzy M., Saunders J.K., et al. The effects of caffeine on ischemic neuronal injury as determined by magnetic resonance imaging and histopathology. Neuroscience 1991, 42:171-182.
232. 2A receptors. Progress in Neurobiology 1999, 59:355-396.
233. Takagi Y., Nozaki K., Sugino T., Hattori I., Hashimoto N. Phosphorylation of c-Jun NH(2)-terminal kinase and p38 mitogen-activated protein kinase after transient forebrain ischemia in mice. Neuroscience Letters 2000, 294:117-120.
234. Tanaka E., Yamamoto S., Kudo Y., Mihara S., Higashi H. Mechanisms underlying the rapid depolarization produced by deprivation of oxygen and glucose in rat hippocampal CA1 neurons in vitro. Journal of Neurophysiology 1997, 78:891-902.
235. Tanaka E., Yasumoto S., Hattori G., Niiyama S., Matsuyama S., Higashi H. Mechanisms underlying the depression of evoked fast EPSCs following in vitro ischemia in rat hippocampal CA1 neurons. Journal of Neurophysiology 2001, 86:1095-1103.
236. 2A receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. Journal of Neurochemistry 2008, 104:279-286.
237. 2B adenosine receptor functioning by tumour necrosis factor a in human astroglial cells. Journal of Neurochemistry 2004, 91:1180-1190.
238. 2A adenosine receptor expression and functioning following permanent focal ischemia in rat brain. Journal of Neurochemistry 2008, 104:479-490.
239. 2B adenosine receptor desensitization in human astroglial cells. Journal of Cellular Biochemistry 2008, 104:150-161.
240. 3 adenosine receptors: Role in receptor desensitization and resensitization. Journal of Neurochemistry 2000, 75:1493-1501.
241. 3 adenosine receptors in human astrocytoma cells: Agonist-mediated desensitization, internalization, and down-regulation. Molecular Pharmacology 2002, 62:1373-1384.
242. 1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:11718-11722.
243. 1 adenosine receptor activation induces ventriculomegaly and white matter loss. Neuroreport 2002, 13:1199-1204.
244. 2A adenosine receptors in human platelet membranes by [3H]-CGS21680 binding. British Journal of Pharmacology 1996, 117:1693-1701.
245. 2A adenosine receptors in human lymphocyte membranes by [3H]-SCH58261 binding. British Journal of Pharmacology 1997, 122:386-392.
246. Varani K., Gessi S., Dionisotti S., Ongini E., Borea P.A. [3H]-SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes. British Journal of Pharmacology 1998, 123:1723-1731.
247. 2B ligands. Journal of Medicinal Chemistry 2002, 45:3271-3279.
248. 3 adenosine receptor. Journal of Medicinal Chemistry 2007, 50:1222-1230.
249. von Arnim C.A., Timmler M., Ludolph A.C., Riepe M.W. Adenosine receptor up-regulation: Initiated upon preconditioning but not upheld. Neuroreport 2000, 11:1223-1226.
250. von Arnim C.A., Verstege E., Etrich S.M., Riepe M.W. Mechanisms of hypoxic tolerance in presymptomatic APP23 transgenic mice. Mechanisms of Ageing and Development 2006, 127:109-114.
251. von Lubitz D.K. Adenosine and cerebral ischemia: Therapeutic future or death of a brave concept?. European Journal of Pharmacology 1999, 371:85-102.
252. von Lubitz D.K., Dambrosia J.M., Kempski O., Redmond D.J. Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of gerbil hippocampus. Stroke 1988, 19:1133-1139.
253. 3 receptor agonist and cerebral ischemia: Neuronal and glial effects. European Journal of Pharmacology 1999, 367:157-163.
254. 2A receptor agonist and antagonist. European Journal of Pharmacology 1995, 287:295-302.
255. 1 receptor agonist or antagonist in cerebral ischemia. European Journal of Pharmacology 1994, 256:161-167.
256. von Lubitz D.K., Lin R.C., Paul I.A., Beenhakker M., Boyd M., Bischofberger N., et al. Postischemic administration of adenosine amine congener (ADAC): Analysis of recovery in gerbils. European Journal of Pharmacology 1996, 316:171-179.
257. 3 receptor stimulation and cerebral ischemia. European Journal of Pharmacology 1994, 263:59-67.
258. von Lubitz D.K., Marangos P.J. Cerebral ischemia in gerbils: Postischemic administration of cyclohexyl adenosine and 8-sulfophenyl-theophylline. Journal of Molecular Neuroscience 1990, 2:53-59.
259. 3 receptors and cerebroprotection in stroke. Annals of the New York Academy of Sciences 2001, 939:85-96.
260. 3 receptors in cerebral ischemia. Neuronal death, recovery, or both?. Annals of the New York Academy of Sciences 1999, 890:93-106.
261. 2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation. Journal of Immunology 2013, 190:138-146.
262. 2A adenosine receptor gene expression in developing rat brain. Brain Research. Molecular Brain Research 1993, 20:313-327.
263. Wei C.J., Li W., Chen J.F. Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochimica et Biophysica Acta 2011, 1808:1358-1379.
264. White P.J., Rose'Meyer R.B., Hope W. Functional characterization of adenosine receptors in the nucleus tractus solitarius mediating hypotensive responses in the rat. British Journal of Pharmacology 1996, 117:305-308.
265. Wu D.C., Ye W., Che X.M., Yang G.Y. Activation of mitogen-activated protein kinases after permanent cerebral artery occlusion in mouse brain. Journal of Cerebral Blood Flow and Metabolism 2000, 20:1320-1330.
266. Yamamoto S., Tanaka E., Shoji Y., Kudo Y., Inokuchi H., Higashi H. Factors that reverse the persistent depolarization produced by deprivation of oxygen and glucose in rat hippocampal CA1 neurons in vitro. Journal of Neurophysiology 1997, 78:903-911.
267. 2A receptor contributes to ischemic brain damage in newborn piglet. Journal of Cerebral Blood Flow and Metabolism 2013, 33:1612-1620.
268. 2B adenosine receptor protects against inflammation and excessive vascular adhesion. The Journal of Clinical Investigation 2006, 116:1913-1923.
269. 1 receptor antagonist and mitochondrial ATP-sensitive potassium channel blocker attenuate the tolerance to focal cerebral ischemia in rats. Journal of Cerebral Blood Flow and Metabolism 2004, 24:771-779.
270. 2A receptor gene by molecular and bioinformatics analyses. Brain Research 2004, 1000:156-173.
271. Yu A.C., Lee Y.L., Fu W.Y., Eng L.F. Gene expression in astrocytes during and after ischemia. Progress in Brain Research 1995, 105:245-253.
272. Zetterstrom T., Fillenz M. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. European Journal of Pharmacology 1990, 180:137-143.
273. Zhang R.L., Chopp M., Chen H., Garcia J.H. Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. Journal of the Neurological Sciences 1994, 125:3-10.
274. Zhou A.M., Li W.B., Li Q.J., Liu H.Q., Feng R.F., Zhao H.G. A short cerebral ischemic preconditioning up-regulates adenosine receptors in the hippocampal CA1 region of rats. Neuroscience Research 2004, 48:397-404.
275. Zhou J.G., Meno J.R., Hsu S.S., Winn H.R. Effects of theophylline and cyclohexyladenosine on brain injury following normo- and hyperglycemic ischemia: A histopathologic study in the rat. Journal of Cerebral Blood Flow and Metabolism 1994, 14:166-173.